Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | FABP4 | P15090 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.50 |
| ▸ | SELP | P16109 | 2/20 | 0.50 |
| ▸ | SELE | P16581 | 2/20 | 0.50 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.50 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13513281 | 0.86 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2NR3C1POLBKEAP1 | |
| SCHEMBL398666 | 0.85 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2FABP4NR3C1POLB | |
| SCHEMBL15834340 | 0.84 | ROCK1 (0.54) | ALDH1A1SMN1; SMN2NR3C1POLBKEAP1 | |
| Hydrochloric Acid SCHEMBL27533178 | 0.84 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2NR3C1POLBKEAP1 | |
| SCHEMBL2767849 | 0.84 | POLB (0.57) | ALDH1A1SMN1; SMN2FABP4NR3C1POLB | |
| SCHEMBL6500179 | 0.84 | FABP4 (0.57) | ALDH1A1SMN1; SMN2FABP4NR3C1POLB | |
| SCHEMBL18722495 | 0.83 | ROCK1 (0.53) | ALDH1A1SMN1; SMN2NR3C1POLBROCK1 | |
| SCHEMBL3560306 | 0.81 | IKBKB (0.58) | ALDH1A1SMN1; SMN2NR3C1POLBKEAP1 | |
| SCHEMBL6122391 | 0.81 | PTPN1 (0.53) | ALDH1A1SMN1; SMN2NR3C1POLBKEAP1 | |
| SCHEMBL12440452 | 0.81 | POLB (0.50) | ALDH1A1SMN1; SMN2NR3C1POLBROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-112920180-A | Glutaminase inhibitors | 理森制药股份公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-105960405-B | Glutaminase inhibitors | 理森制药股份公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20210032236-A1 | NOVEL GLUTAMINASE INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2021-02-04 | — | — | US | disclosed |
| CN-111892589-A | Glutaminase inhibitors | 理森制药股份公司 | 2020-11-06 | — | — | CN | disclosed |
| EP-3092236-B1 | NOVEL GLUTAMINASE INHIBITORS | RHIZEN PHARMACEUTICALS S A (CH) | 2020-08-26 | — | — | EP | disclosed |
| CN-106029659-B | Glutaminase inhibitors | 理森制药股份公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111393431-A | Glutaminase inhibitors | 理森制药股份公司 | 2020-07-10 | — | — | CN | disclosed |
| US-10611759-B2 | Glutaminase inhibitors | RHIZEN PHARMACEUTICALS SA (CH) | 2020-04-07 | — | — | US | disclosed |
| US-20180057487-A1 | NOVEL GLUTAMINASE INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2018-03-01 | — | — | US | disclosed |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | GLAXO GROUP LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
| WO-2005019190-A2 | (4 -AMINO -1,2, 5-OXADIAZOL-4-YL) -HETΞROAROMATIC COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1492537-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| EP-1487453-A1 | N- [(2S)-4-(3,4-DIFLUOROBENZYL)MORPHOLIN-2-YL]METHYL -2- 3-[(METHYLSULPHONYL)AMINO]PHENYL ACETAMIDE AS CCR3 ANTAGONIST FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | disclosed |
| WO-2003082294-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082291-A1 | N-{´ (2S) -4- (3, 4-DIFLUOROBENZYL) MORPHOLIN-2YL!METHYL} -2-{3-' (METHYLSULPHONYL) AMINO! PHENYL}ACETAMIDE AS CCR3 ANTAGONIST FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| EP-1324990-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026722-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032236-A1 | NOVEL GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | ALDH1A1 1082/4885SMN1; SMN2 2272/4885FABP4 870/4885 |
| US-20180057487-A1 | NOVEL GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | ALDH1A1 1082/4885SMN1; SMN2 2272/4885FABP4 870/4885 |
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | PHKG1, MAP3K20, MAP3K5 | ALDH1A1 2638/4885SMN1; SMN2 2544/4885FABP4 1792/4885 |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | CCR1, MALT1, REL | ALDH1A1 3130/4885SMN1; SMN2 1217/4885FABP4 2878/4885 |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | NISCH, MYO3B, CYP11B2 | ALDH1A1 1003/4885SMN1; SMN2 709/4885FABP4 3581/4885 |
| US-10611759-B2 | Glutaminase inhibitors | GLS, GLS2, GLUL | ALDH1A1 837/4885SMN1; SMN2 1928/4885FABP4 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.